Get in touch

Sterile Injectable Manufacturing in India: What Global Pharma Companies Should Look for in a CDMO

Sterile injectable products leave very little room for manufacturing error. Unlike many conventional dosage forms, injectables must be manufactured under tightly controlled conditions because the finished drug is administered directly into the body. For pharmaceutical companies, choosing the right sterile injectable CDMO is therefore not simply a capacity or cost decision. It is a decision involving product quality, aseptic processing, technical capability, regulatory readiness, supply reliability and long-term commercial scalability.

India has become an important destination for sterile injectable manufacturing, pharmaceutical development and contract manufacturing. Global pharmaceutical companies increasingly evaluate Indian partners for development, technology transfer, clinical and commercial manufacturing, particularly when they need a combination of technical expertise and scalable infrastructure.

The requirements become even more specialized in oncology. An oncology injectables manufacturer may need to manage potent or cytotoxic compounds while maintaining stringent contamination-control and sterile-processing standards. This combination requires more than a conventional injectable manufacturing facility.

For companies searching for a sterile injectable CDMO in India, the right question is not simply, “Can this company manufacture our product?”

The better question is:

“Does this CDMO have the technical systems, quality culture, containment strategy, regulatory understanding and manufacturing infrastructure required to support our product throughout its lifecycle?”

This guide examines the key factors pharmaceutical companies should consider before selecting a sterile injectable manufacturing partner.

What Is a Sterile Injectable CDMO?

A sterile injectable CDMO is a Contract Development and Manufacturing Organization with capabilities to support the development and manufacturing of sterile injectable pharmaceutical products.

Depending on the CDMO’s capabilities and the product requirements, support may extend across:

This integrated model can be particularly valuable when a pharmaceutical company wants to reduce the number of handoffs between development and manufacturing partners.

Every transfer between organizations introduces additional coordination, documentation and technical-transfer requirements. Working with a capable CDMO can create greater continuity from development through commercial production.

Why Is Sterile Injectable Manufacturing More Complex?

Sterile manufacturing presents challenges that differ significantly from conventional pharmaceutical production.

The finished product must meet stringent requirements for sterility and quality while the manufacturing environment, equipment, personnel and processes must operate under carefully controlled conditions.

Aseptic Processing

Aseptic manufacturing requires control over every point at which the sterile product or sterile components could potentially be exposed.

This makes facility design, environmental monitoring, personnel practices, equipment qualification and validated manufacturing procedures essential parts of the overall contamination-control strategy.

A prospective CDMO should therefore demonstrate more than the presence of a sterile filling line. Pharmaceutical companies should evaluate the entire system supporting aseptic production.

Contamination Control

Contamination can arise from people, equipment, materials, processes or the surrounding environment.

An effective sterile manufacturing operation should have systems designed to identify, control and continuously monitor these risks.

For sterile oncology manufacturing in India, this consideration becomes even more important because certain products may also require specialized containment to protect operators and prevent cross-contamination.

Process Consistency

Injectable products require consistent execution across preparation, filtration where applicable, filling, closure and downstream handling.

Minor variations can create significant product-quality consequences.

For this reason, the quality of a sterile injectable manufacturing partner depends as much on process discipline and technical knowledge as it does on installed equipment.

1. Evaluate the CDMO’s Sterile Manufacturing Infrastructure

The first area to assess is the manufacturing environment itself.

A strong injectable manufacturing company in India should have infrastructure appropriate to the dosage forms and processes it intends to support.

Evaluation should consider areas such as:

The important point is to evaluate the facility as an integrated manufacturing system rather than judging individual pieces of equipment in isolation.

For example, advanced filling technology has limited value if the surrounding contamination-control, maintenance, validation and quality systems are not equally robust.

2. Look for Experience with the Relevant Dosage Form

Not every sterile manufacturing facility has the same expertise.

A company experienced primarily in one type of injectable product may not automatically be the ideal partner for another.

Before selecting a sterile injectable CDMO, pharmaceutical companies should assess experience with the specific dosage form, formulation characteristics and manufacturing challenges associated with their product.

For example, requirements can differ between liquid injectables and lyophilized products.

A technically experienced CDMO should understand these differences and be capable of identifying potential manufacturing risks before they become expensive scale-up or commercial-production problems.

3. Consider Liquid and Lyophilized Injectable Capabilities

Some pharmaceutical products are suitable for liquid presentation, while others require lyophilization to achieve the desired stability and shelf-life characteristics.

Lyophilization adds another layer of technical complexity to sterile manufacturing.

A CDMO supporting lyophilized products may need expertise in areas such as formulation behavior, freezing, primary drying, secondary drying, cycle development and scale-up.

For companies developing products that require freeze-drying, access to both sterile filling and lyophilization capabilities can simplify the manufacturing pathway.

It can also reduce the operational complexity associated with moving a sterile product between multiple manufacturing partners.

4. Assess Oncology and High-Potency Manufacturing Expertise

Sterile oncology products can require an especially specialized manufacturing environment.

Many oncology compounds involve potent or cytotoxic materials that demand appropriate handling and containment.

This means the selected partner should understand both:

sterile product protection and high-potency containment.

A CDMO involved in high-potency pharmaceutical manufacturing should have systems designed to manage occupational exposure, material movement, cleaning, waste handling and cross-contamination risks.

This is one of the reasons pharmaceutical companies developing oncology products should consider specialized oncology manufacturing experience rather than evaluating only general sterile capacity.

An experienced oncology injectables manufacturer is more likely to understand the combination of product-quality, containment and operational requirements involved in bringing such products into commercial production.

5. Examine Quality Systems, Not Just Certifications

Regulatory credentials matter, but pharmaceutical companies should look deeper than a list of certifications.

A strong quality system should be embedded into everyday manufacturing operations.

When evaluating a potential sterile injectable CDMO, companies should examine how the organization approaches:

The objective is to understand how consistently the CDMO manages quality throughout the manufacturing lifecycle.

A mature quality culture can become particularly important when products move from development batches into routine commercial manufacturing.

6. Evaluate R&D and Formulation Development Support

The strongest manufacturing partnerships often begin before commercial production.

A CDMO with pharmaceutical R&D capabilities can help address formulation and process challenges earlier in development.

This may include analytical development, stability evaluation, formulation optimization and process development.

Early collaboration between R&D and manufacturing teams can also make subsequent scale-up more efficient because manufacturing considerations are incorporated before the process reaches commercial scale.

For pharmaceutical companies, this creates a more connected pathway:

Development → Scale-Up → Technology Transfer → Validation → Commercial Manufacturing

Selecting a partner capable of supporting multiple stages can reduce fragmentation and improve technical continuity.

7. Study the CDMO’s Technology Transfer Process

Technology transfer is one of the most critical stages in pharmaceutical outsourcing.

A process that performs successfully in a development environment must be reproduced reliably using different equipment, batch sizes, facilities and operating conditions.

This requires systematic knowledge transfer.

A capable CDMO should establish a structured transfer process covering areas such as:

Poor technology transfer can cause delays, repeated batches and unexpected process deviations.

For global pharmaceutical companies evaluating CDMO services in India, technology-transfer capability should therefore be considered a major selection criterion rather than a routine administrative step.

8. Check the Ability to Scale from Development to Commercial Supply

A successful development batch does not automatically guarantee successful commercial production.

As batch sizes increase, process behavior can change.

Mixing, heat transfer, filtration, filling and other manufacturing parameters may behave differently at commercial scale.

This is why pharmaceutical companies should understand how the CDMO approaches scale-up.

Ideally, the partner should be capable of supporting the transition from formulation development through commercial manufacturing without losing process knowledge between teams.

A connected scale-up model can reduce technical gaps and make commercial readiness more predictable.

9. Review Commercial Manufacturing Capacity and Supply Reliability

Technical capability is only one side of CDMO selection.

The partner must also be able to supply the product reliably.

Before entering a long-term manufacturing relationship, pharmaceutical companies should evaluate:

The right partner should be able to support current requirements while also accommodating future growth.

This is especially relevant for products that may enter additional markets or experience increased demand after launch.

10. Consider Regulatory and Market Readiness

Global pharmaceutical programs often target multiple regulated markets.

Manufacturing documentation, quality systems and regulatory support therefore need to align with the intended commercialization strategy.

A sterile injectable CDMO in India serving international pharmaceutical companies should understand the expectations associated with regulated markets and maintain documentation accordingly.

Regulatory readiness should not begin only when a submission is approaching.

It should be built into development, analytical work, manufacturing documentation and quality systems from the beginning.

This approach reduces the risk of having to reconstruct critical information later in the product lifecycle.

11. Evaluate Communication and Project Management

CDMO partnerships are ultimately collaborative relationships.

Even technically strong organizations can create difficulties if communication between the sponsor and manufacturing teams is inconsistent.

Global pharmaceutical companies should therefore evaluate how prospective partners manage:

Transparent communication becomes especially important during technology transfer, validation, regulatory preparation and commercial launch.

The ideal CDMO should operate as an extension of the pharmaceutical company’s development and manufacturing team rather than simply as an external production vendor.

Why India Is an Important Destination for Sterile Injectable Manufacturing

India has developed a significant pharmaceutical manufacturing ecosystem spanning drug development, analytical services, formulation manufacturing and commercial production.

For global pharmaceutical companies, pharmaceutical contract manufacturing in India can provide access to experienced scientific and manufacturing talent together with established pharmaceutical infrastructure.

But partner selection should never be based on geography or cost alone.

Sterile manufacturing requires specialized capability.

The right Indian CDMO should demonstrate a combination of:

For oncology products, specialized high-potency and cytotoxic handling capabilities become additional considerations.

What Makes an Oncology-Focused Sterile CDMO Different?

An oncology-focused CDMO operates at the intersection of several technically demanding areas.

It may need to manage potent compounds, sterile manufacturing requirements, complex formulations, specialized containment and stringent quality controls within the same product lifecycle.

This creates a different capability profile from that of a general pharmaceutical manufacturer.

For pharmaceutical companies developing oncology therapies, a specialized partner can offer deeper understanding of the challenges associated with:

This specialization can be particularly valuable when development timelines are tight and the manufacturing process must transition efficiently toward commercialization.

Choosing a Sterile Injectable CDMO: A Practical Checklist

Before finalizing a manufacturing partner, pharmaceutical companies should ask several practical questions:

The answers provide a much clearer picture than manufacturing capacity alone.

Teyro: Specialized CDMO Capabilities for Oncology and Sterile Manufacturing

Teyro brings together pharmaceutical development and manufacturing capabilities with a strong focus on oncology, high-potency products and sterile manufacturing.

Its capabilities span R&D, formulation development, analytical and stability activities, technology transfer, scale-up and commercial manufacturing. Teyro’s manufacturing infrastructure supports sterile and non-sterile dosage forms, including liquid and lyophilized injectables.

For pharmaceutical companies seeking an oncology CDMO company or sterile injectable CDMO, this integrated approach can support continuity as a product progresses from development toward commercial manufacturing.

The value of such a partnership lies not simply in manufacturing a batch, but in building a reliable pathway from pharmaceutical development to market supply.

Conclusion

Choosing the right sterile injectable CDMO requires much more than comparing production capacity and commercial quotations.

Pharmaceutical companies should evaluate the complete manufacturing ecosystem: sterile infrastructure, aseptic controls, dosage-form experience, quality systems, containment, R&D support, technology transfer, scale-up capability, regulatory readiness and commercial supply.

These factors become even more important for oncology and high-potency products.

A CDMO that combines development expertise with sterile injectable manufacturing and commercial-scale capabilities can help reduce handoffs, preserve product knowledge and create a more connected route from development to market.

For global pharmaceutical companies evaluating sterile injectable manufacturing in India, the strongest partner will be one capable of supporting not only today’s manufacturing requirement, but the product’s entire commercial journey.

Suggested CTA

Looking for a specialized partner for sterile injectable or oncology manufacturing?

Connect with Teyro to explore development, technology transfer, scale-up and commercial manufacturing support for complex pharmaceutical products.